CL2013000223A1 - Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion. - Google Patents

Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.

Info

Publication number
CL2013000223A1
CL2013000223A1 CL2013000223A CL2013000223A CL2013000223A1 CL 2013000223 A1 CL2013000223 A1 CL 2013000223A1 CL 2013000223 A CL2013000223 A CL 2013000223A CL 2013000223 A CL2013000223 A CL 2013000223A CL 2013000223 A1 CL2013000223 A1 CL 2013000223A1
Authority
CL
Chile
Prior art keywords
hmgb1
kit
realization
detection
inflammatory bowel
Prior art date
Application number
CL2013000223A
Other languages
English (en)
Spanish (es)
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Original Assignee
Dmg Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmg Italia Srl filed Critical Dmg Italia Srl
Publication of CL2013000223A1 publication Critical patent/CL2013000223A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2013000223A 2010-08-05 2013-01-23 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion. CL2013000223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Publications (1)

Publication Number Publication Date
CL2013000223A1 true CL2013000223A1 (es) 2014-03-28

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000223A CL2013000223A1 (es) 2010-08-05 2013-01-23 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.

Country Status (14)

Country Link
US (1) US20130137123A1 (enExample)
EP (1) EP2601525A1 (enExample)
JP (1) JP2013534313A (enExample)
CN (1) CN103069276A (enExample)
AU (1) AU2011287193B2 (enExample)
BR (1) BR112013002145A2 (enExample)
CA (1) CA2807107C (enExample)
CL (1) CL2013000223A1 (enExample)
EA (1) EA201390197A1 (enExample)
IL (1) IL223845A (enExample)
IT (1) IT1406051B1 (enExample)
MX (1) MX2013001327A (enExample)
PE (1) PE20131062A1 (enExample)
WO (1) WO2012017466A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
ES2944359T3 (es) 2017-05-12 2023-06-20 Evonik Operations Gmbh Procedimiento de detección de enfermedades inducidas por C. perfringens en una bandada de aves
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20200128413A (ko) * 2018-03-02 2020-11-12 에보니크 오퍼레이션즈 게엠베하 오보트랜스페린을 결정함으로써 동물에서의 장 장벽 기능상실을 검출하기 위한 시험관내 방법
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112021011158A2 (pt) 2018-12-14 2021-08-31 Evonik Operations Gmbh Método in vitro para detectar disbiose intestinal aviária, uso do dito método e uso de isoleucil-arginina ou isômeros desta
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法
CN117825719B (zh) * 2024-01-04 2026-07-17 复旦大学附属中山医院 用于嗜酸性肉芽肿性多血管炎诊断的蛋白质组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
WO2004079368A2 (en) * 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
JP2008520552A (ja) * 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
EA201000131A1 (ru) * 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника
KR20100124326A (ko) * 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커

Also Published As

Publication number Publication date
CA2807107C (en) 2017-01-03
WO2012017466A1 (en) 2012-02-09
CN103069276A (zh) 2013-04-24
CA2807107A1 (en) 2012-02-09
EA201390197A1 (ru) 2013-06-28
AU2011287193A1 (en) 2013-06-13
WO2012017466A8 (en) 2013-07-11
BR112013002145A2 (pt) 2016-05-24
US20130137123A1 (en) 2013-05-30
AU2011287193B2 (en) 2015-08-13
ITRM20100442A1 (it) 2012-02-06
MX2013001327A (es) 2013-03-08
EP2601525A1 (en) 2013-06-12
PE20131062A1 (es) 2013-10-16
IT1406051B1 (it) 2014-02-06
JP2013534313A (ja) 2013-09-02
IL223845A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112013002145A2 (pt) uso de hmgb1 como um marcador biológico das condições inflamatórias intestinais, método não-invasivo para detecção das mesmas em amostras fecais e respectivo kit
IL233098A0 (en) Ratio based biomarkers and methods of use thereof
IL254144A0 (en) Methods for reprogramming cells and uses thereof
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI1009420A2 (pt) axmi-001, axmi-002, axmi-030, e axmi-045; genes de toxina e métodos para seu uso
BRPI1012861A2 (en) catalyst and catalyst use
BRPI0819956A2 (pt) Métodos e aparelhos de nova seleção celular.
BRPI1010774A2 (pt) método de uso de particulados.
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BRPI1011321A2 (pt) dispositivo de monitoramento de analito de métodos de uso
EP2338989A4 (en) METHOD OF PREPARING AN FECAL SAMPLE, PREPARATION SOLUTION OF AN FECAL SAMPLE, AND KIT FOR COLLECTING FECES
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BR112012001043A2 (pt) tinturas fluorescentes e uso das mesmas
BRPI0915086A2 (pt) detecção do uso de canabis
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas
BRPI1006996A2 (pt) composição, método e uso
BRPI0924225A2 (pt) linhagens de células que expressam nav e métodos de uso
BRPI1007397A2 (pt) misturas de borrachas, método para a fabricação das misturas de borrachas e seu uso
BRPI0920222A2 (pt) composições catalisadoras e métodos de produção e uso das mesmas
BRPI1013671A2 (pt) método para o diagnóstico de endometriose e kit de diagnóstico para endometriose
BRPI0924180A2 (pt) lacases e métodos de uso das mesmas em baixa temperatura
BRPI0814988A2 (pt) Hidridização in-situ para detectar marcadores de rna e dna.
BR112012014678A2 (pt) "uso do dna mrna, método para o diagnóstico da rosácea e método de monitoramento"
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
EP2426495A4 (en) METHOD FOR DETECTING KIDNEY DISEASE BY MEASURING HUMAN MEGALIN IN THE HARN